Vivos Therapeutics, Inc.
VVOS
$2.63
-$0.08-2.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.91% | 0.54% | -9.23% | -17.70% | -13.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.91% | 0.54% | -9.23% | -17.70% | -13.87% |
| Cost of Revenue | 8.72% | -6.18% | -8.72% | -14.61% | -7.91% |
| Gross Profit | 9.04% | 5.19% | -9.57% | -19.72% | -17.45% |
| SG&A Expenses | -21.38% | -22.36% | -27.55% | -27.84% | -27.12% |
| Depreciation & Amortization | -6.59% | -8.72% | -11.54% | -12.92% | -6.89% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.74% | -19.71% | -24.49% | -25.80% | -24.34% |
| Operating Income | 35.40% | 34.99% | 35.72% | 31.42% | 31.02% |
| Income Before Tax | 18.02% | 18.46% | 35.77% | 22.63% | 43.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.02% | 18.46% | 35.77% | 22.63% | 43.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.02% | 18.46% | 35.77% | 22.63% | 43.04% |
| EBIT | 35.40% | 34.99% | 35.72% | 31.42% | 31.02% |
| EBITDA | 36.48% | 35.90% | 36.50% | 31.60% | 31.68% |
| EPS Basic | 70.86% | 56.60% | 61.46% | 49.37% | 57.81% |
| Normalized Basic EPS | 70.86% | 56.66% | 61.50% | 49.42% | 60.14% |
| EPS Diluted | 70.86% | 56.60% | 61.46% | 49.37% | 57.81% |
| Normalized Diluted EPS | 70.86% | 56.66% | 61.50% | 49.42% | 60.14% |
| Average Basic Shares Outstanding | 254.87% | 148.68% | 95.46% | 60.13% | 30.50% |
| Average Diluted Shares Outstanding | 254.87% | 148.68% | 95.46% | 60.13% | 30.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |